Literature DB >> 10951417

Initial experience with breast biopsy utilizing the Advanced Breast Biopsy Instrumentation (ABBI).

G Portincasa1, E Lucci, G G Navarra, S Donato, R Parpanesi, D Garcea.   

Abstract

The Advanced Breast Biopsy Instrumentation (ABBI) system combines a cylindrical single-use biopsy device with digital stereotactic imaging that achieves targeting of radiographic lesions to +/- 1 mm. This minimally invasive technique uses digital stereotactic imaging to perform excisional biopsies of suspicious, nonpalpable mammographic lesion. This allows complete removal of specimens in a one-step procedure that does not involve separate trips to radiology and then surgery. The authors' initial 170 cases utilizing the ABBI system were reviewed. The accuracy of specimen targeting, the success rate of lesion removal, and operative complications were some of the issues assessed. Five cases were not suitable for the procedure: the mammographic lesion was not visualized in one, and the breast was too thin on compression in four. There was successful removal of the lesion in 165 of the remaining cases. There were no local wound complications, and patient satisfaction was high in all completed biopsies. The ABBI system is an effective new form of minimally invasive breast surgery. It provides complete excision of mammographic abnormalities.

Entities:  

Mesh:

Year:  2000        PMID: 10951417     DOI: 10.1002/1096-9098(200007)74:3<201::aid-jso8>3.0.co;2-5

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Mammotome: less invasive than ABBI with similar accuracy for early breast cancer detection.

Authors:  Walter P Weber; Rosanna Zanetti; Igor Langer; Sophie Dellas; Markus Zuber; Holger Moch; Eugenia Remmel; Daniel Oertli; Edward Wight; Walter R Marti
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

2.  The use of stereotactic excisional biopsy in the management of invasive breast cancer.

Authors:  Waël C Hanna; Sebastian V Demyttenaere; Lorenzo E Ferri; David M Fleiszer
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.